Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment

Endometrial cancer (EC), while generally curable in early stages, poses significant challenges when it recurs or advances. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors, have provided a promising therapeutic option for such cases, especially with FDA-approved drugs...

Full description

Bibliographic Details
Authors: Albertí Valls, Manel, Olave, Sara, Olomí, Anna, Macià Armengol, Anna, Eritja Sánchez, Núria
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/467181
Online Access:https://doi.org/10.3390/cancers16233918
https://hdl.handle.net/10459.1/467181
Access Level:Open access
Keyword:Endometrial cancer
Immunotherapy
Mismatch repair
Tumor mutational burden
Tumor microenvironment
Immune checkpoint blockade
Cell-based therapies
id ES_cdb6a2f3fd04df210e97ac6d30c0661a
oai_identifier_str oai:recercat.cat:10459.1/467181
network_acronym_str ES
network_name_str España
repository_id_str
spelling Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor MicroenvironmentAlbertí Valls, ManelOlave, SaraOlomí, AnnaMacià Armengol, AnnaEritja Sánchez, NúriaEndometrial cancerImmunotherapyMismatch repairTumor mutational burdenTumor microenvironmentImmune checkpoint blockadeCell-based therapiesEndometrial cancer (EC), while generally curable in early stages, poses significant challenges when it recurs or advances. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors, have provided a promising therapeutic option for such cases, especially with FDA-approved drugs like pembrolizumab, durvalumab, and dostarlimab. The molecular classification of EC, particularly mismatch repair deficiency, has proven essential in identifying tumors that are likely to respond to immune checkpoint inhibitors, owing to their increased tumor mutational burden and higher PD-L1 expression. However, mismatch repair (MMR) status alone is insufficient to predict immune responses as treatment outcomes are also substantially influenced by tumor microenvironment composition, immune infiltration, and inter-individual variability. Emerging cell therapies like Chimeric Antigen Receptor (CAR) T cells and tumor-infiltrating lymphocytes offer hope for addressing non-immunogenic tumors, overcoming immune evasion mechanisms that limit natural immune responses.This work has been funded by the Instituto de Salud Carlos III (ISCIII) through the projects PI20/00502, CP19/00025, CB16/12/00231, Cofounded by European Regional Development Fund (ERDF) ‘a way to make Europe’ and ESF ‘Investing in your future’) and the Fundación Contigo Contra el Cáncer de la Mujer. We also thank the grups consolidats de la Generalitat de Catalunya (2021SGR00093). M.A.-V. holds a predoctoral fellowship from the Universitat de Lleida.MDPI2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.3390/cancers16233918https://hdl.handle.net/10459.1/467181reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.3390/cancers16233918Cancers, 2024, vol. 16, núm. 3918.cc-by, (c) Albertí et al., 2024Attribution 4.0 Internationalinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/4671812026-05-29T05:05:01Z
dc.title.none.fl_str_mv Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
title Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
spellingShingle Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
Albertí Valls, Manel
Endometrial cancer
Immunotherapy
Mismatch repair
Tumor mutational burden
Tumor microenvironment
Immune checkpoint blockade
Cell-based therapies
title_short Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
title_full Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
title_fullStr Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
title_full_unstemmed Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
title_sort Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
dc.creator.none.fl_str_mv Albertí Valls, Manel
Olave, Sara
Olomí, Anna
Macià Armengol, Anna
Eritja Sánchez, Núria
author Albertí Valls, Manel
author_facet Albertí Valls, Manel
Olave, Sara
Olomí, Anna
Macià Armengol, Anna
Eritja Sánchez, Núria
author_role author
author2 Olave, Sara
Olomí, Anna
Macià Armengol, Anna
Eritja Sánchez, Núria
author2_role author
author
author
author
dc.subject.none.fl_str_mv Endometrial cancer
Immunotherapy
Mismatch repair
Tumor mutational burden
Tumor microenvironment
Immune checkpoint blockade
Cell-based therapies
topic Endometrial cancer
Immunotherapy
Mismatch repair
Tumor mutational burden
Tumor microenvironment
Immune checkpoint blockade
Cell-based therapies
description Endometrial cancer (EC), while generally curable in early stages, poses significant challenges when it recurs or advances. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors, have provided a promising therapeutic option for such cases, especially with FDA-approved drugs like pembrolizumab, durvalumab, and dostarlimab. The molecular classification of EC, particularly mismatch repair deficiency, has proven essential in identifying tumors that are likely to respond to immune checkpoint inhibitors, owing to their increased tumor mutational burden and higher PD-L1 expression. However, mismatch repair (MMR) status alone is insufficient to predict immune responses as treatment outcomes are also substantially influenced by tumor microenvironment composition, immune infiltration, and inter-individual variability. Emerging cell therapies like Chimeric Antigen Receptor (CAR) T cells and tumor-infiltrating lymphocytes offer hope for addressing non-immunogenic tumors, overcoming immune evasion mechanisms that limit natural immune responses.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/cancers16233918
https://hdl.handle.net/10459.1/467181
url https://doi.org/10.3390/cancers16233918
https://hdl.handle.net/10459.1/467181
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.3390/cancers16233918
Cancers, 2024, vol. 16, núm. 3918.
dc.rights.none.fl_str_mv cc-by, (c) Albertí et al., 2024
Attribution 4.0 International
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by, (c) Albertí et al., 2024
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419879608614912
score 15,812429

Similar Items